EDISON EQUITY RESEARCH: SQI DIAGNOSTICS

EDISON EQUITY RESEARCH:SQI DIAGNOSTICS - TAPPING INTO CONSIDERABLE MARKET OPPORTUNITIES

SQI has made steady progress over recent months in signing new agreements with drug development companies in its high-volume assay business. Encouragingly, service revenues are now booked for custom-made tests early on in development, albeit at modest levels. While the conversion of customers from early contract work/validation to meaningful revenue-generating accounts is slower than expected, industry interest continues to grow steadily for SQI’s multiplexing technology capabilities, as does its pipeline of potential customers.

SQI Diagnostics is a Canadian diagnostics company. It develops and sells multiplexed research diagnostics to pharmaceutical companies to support clinical research and in vitro diagnostics tests to centralised diagnostics labs for diagnosing autoimmune diseases.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports